Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARCT
SELLREMOVEArcturus Therapeutics Holdings Inc. · Healthcare · United States · $225M · Avg Vol: $3M/d
Arcturus Therapeutics is a clinical-stage mRNA biotech. While its platform is technologically interesting, it lacks the proven, high-utilization manufacturing moat of an established CDMO and is highly speculative, failing the Buffett and Smith quality filters.
COMPANY DESCRIPTION
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger RNA (mRNA) medicines company focused on the development of infectious disease vaccines and therapies for rare diseases. The company's competitive moat is anchored by its proprietary LUNAR lipid-mediated delivery platform and STARR self-amplifying mRNA technology, which offer potential advantages in dosing and efficacy. It operates as a highly collaborative biotechnology innovator, leveraging strategic partnerships with global pharmaceutical leaders to fund and commercialize its pipeline.
FINANCIAL SUMMARY
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 206M | 158M | 138M | 67M | -31.1% |
| EPS | — | 0.35 | -1.00 | -3.00 | -2.40 | — |
| Shares | — | 27M | 27M | 27M | 28M | +7.0% |
| Debt | 41M | 95M | 30M | 29M | 25M | -11.4% |
| Equity | — | 270M | 279M | 241M | 214M | -7.5% |
| Op CF | — | 32M | -18M | -60M | -74M | — |
| Inv CF | — | -8M | -3M | -648,000 | -230,000 | — |
| Fin CF | — | -3M | -24M | 5M | 13M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARCT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARCT | Arcturus Therapeutics Holdings Inc.(you) | $225M | 22 | SELL |
| OBIO | Orchestra BioMed Holdings, Inc. | $238M | 22 | SELL |
| RNAC | Cartesian Therapeutics, Inc. | $212M | 23 | SELL |
| CNTN | Canton Strategic Holdings, Inc. | $217M | 24 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $270M | 22 | SELL |
| RNA | Atrium Therapeutics, Inc. | $229M | 17 | STRONG SELL |
| VYGR | Voyager Therapeutics, Inc. | $236M | 17 | STRONG SELL |
| RZLT | Rezolute, Inc. | $315M | 21 | SELL |
| CHRS | Coherus Oncology, Inc. | $255M | 17 | STRONG SELL |
| KROS | Keros Therapeutics, Inc. | $225M | 14 | STRONG SELL |
Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%